Draft:Shawn Owen
| Submission declined on 29 June 2024 by Mgp28 (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: Needs to have multiple secondary, reliable, independent sources with significant coverage. Most of the current sources are written by the subject of the article or his employer. References like a list of prize recipients are not significant coverage. Also, there should not be external links in the body of the text. See WP:ELPOINTS. Mgp28 (talk) 10:59, 29 June 2024 (UTC)
Shawn Owen is an Associate Professor of Molecular Pharmaceutics and Adjunct Associate Professor of Biomedical Engineering and Medicinal Chemistry at the University of Utah.[1]. The Owen Lab develops therapies and diagnostics using chemical biology approaches[2]
Shawn Owen | |
|---|---|
| Alma mater | University of Utah |
| Scientific career | |
| Fields | Antibody Drug Conjugates, Therapeutic Fusion Proteins, Bioconjugation Chemistry |
| Doctoral advisor | Molly Shoichet |
| Website | https://owenlab.com/ |
Education
[edit]As a native of Utah, Dr. Owen attended the University of Utah as an undergraduate student from 2000-2005. During his undergraduate education, he double majored and obtained a B.S. in Chemistry with a Biological focus and a B.A. in Chinese. Following his undergraduate studies, he opted to spend another 4 years at the University of Utah for his Ph.D. in Pharmaceutical Chemistry (2005-2009). Under Charles B. Grissom (Ph.D.), Owen gained diverse training in pharmaceutics, chemistry, and biomedical engineering while working on targeted drug delivery.[1]. Following his Ph.D., Owen went on to the Institute for Biomaterials and Biomedical Engineering, University of Toronto (2009-2013) for his Postdoctoral studies under the guidance of Molly Shoichet FRSC, a distinguished Canadian scientist with a broad skill set in chemistry, biomaterials, and biomedical engineering[1]
Career and Research
[edit]After receiving his doctorate degree, Dr. Owen went back to join the University of Utah as an Adjunct Assistant Professor in Internal Medicine and as an Assistant Professor in Pharmaceutics and Pharmaceutical Chemistry (2014-2022). Currently, his positions include Associate Professor of Molecular Pharmaceutics (2022-present) and Adjunct Associate Professor of Biomedical Engineering (2016-present), Medicinal Chemistry (2017-present) at the University of Utah.
The Owen Lab at the University of Utah focuses on developing therapies and diagnostics through chemical biology approaches. Research revolves around utilizing bioconjugation techniques and protein engineering to build new molecules for therapeutic effects such as hybrid molecules[2]. Continued efforts on antibody drug conjugates as well as fused proteins are becoming increasingly important methods to provide a localized effect to better treat a range of diseases[3]. Recent advances in antibody technology have enabled the fusion of antibodies as targeting domains and therapeutic proteins which can be engineered to target different antigens to produce a pharmacological effect[4].
Antibodies are often used for the delivery of small molecule cytotoxins directly to diseased cells. In antibody-directed enzyme prodrug therapy (ADEPT), antibodies are armed with enzymes that activate nontoxic prodrugs at tumor sites[5]. This has not been effective clinically due to the off-target toxicity of the therapy. The Owen Lab designed an antibody-fragment split enzyme platform that is only active when binding to HER2, allowing for site-specific activation of a small molecule prodrug. They screened for the optimal split enzyme pair and evaluation of this system on HER2-positive cells revealed higher toxicity of the activated prodrug over prodrug treatment alone.
The Owen Lab has also developed an assay to detect antibodies that bind to the spike protein of SARS-CoV-2[6]. Their assay measures the neutralization activity of antibodies from convalescent or vaccinated sera, enabling rapid assessment of the effectiveness of vaccines and level of protection against existing and emerging variants of the virus.
Overall, Dr. Owen's lab has demonstrated the effectiveness of therapeutic fusion proteins against a known clinical target. The exponential emergence of biopharmaceuticals encourages increased research into therapeutic fusion proteins for a multitude of diseases.[3]
Awards and Honors
[edit]- College of Pharmacy, Professional Year Two Teacher of the Year, 2022[7]
- College of Pharmacy, Distinguished Teacher of the Year, University of Utah, 2016[8]
- College of Pharmacy, Professional Year One Teacher of the Year, University of Utah, 2016[8]
- Controlled Release Society T. Nagai Postdoctoral Research Achievement Award, 2013[9]
External Links
[edit]References
[edit]- ^ a b c "People – Owen Lab – University of Utah". Retrieved 2024-04-22.
- ^ a b "Research – Owen Lab – University of Utah". Retrieved 2024-04-22.
- ^ a b Marsh, Morgan C.; Owen, Shawn C. (2023-11-30). "Therapeutic Fusion Proteins". The AAPS Journal. 26 (1): 3. doi:10.1208/s12248-023-00873-8. ISSN 1550-7416. PMID 38036919.
- ^ Arlotta, Keith J.; Owen, Shawn C. (September 2019). "Antibody and antibody derivatives as cancer therapeutics". Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology. 11 (5): e1556. doi:10.1002/wnan.1556. ISSN 1939-0041. PMID 30968595.
- ^ Nervig, Christine S.; Hatch, Samuel T.; Owen, Shawn C. (2022-10-31). "Complementation Dependent Enzyme Prodrug Therapy Enables Targeted Activation of Prodrug on HER2-Positive Cancer Cells". ACS Medicinal Chemistry Letters. 13 (11): 1769–1775. doi:10.1021/acsmedchemlett.2c00394. ISSN 1948-5875. PMC 9661694. PMID 36385932.
- ^ Kim, Sun Jin; Yao, Zhong; Marsh, Morgan C.; Eckert, Debra M.; Kay, Michael S.; Lyakisheva, Anna; Pasic, Maria; Bansal, Aiyush; Birnboim, Chaim; Jha, Prabhat; Galipeau, Yannick; Langlois, Marc-André; Delgado, Julio C.; Elgort, Marc G.; Campbell, Robert A. (2022-07-01). "Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies". Nature Communications. 13 (1): 3716. Bibcode:2022NatCo..13.3716K. doi:10.1038/s41467-022-31300-9. ISSN 2041-1723. PMC 9249905. PMID 35778399.
- ^ "Dr. Owen Named 2022 P2 Class Teacher of the Year | College of Pharmacy". pharmacy.utah.edu. 2022-05-16. Retrieved 2024-04-22.
- ^ a b "Alumni Newsletter | 2016 In Review by U of U College of Pharmacy - Issuu". issuu.com. 2017-02-15. Retrieved 2024-04-22.
- ^ "CRS T. Nagai Postdoctoral Research Achievement Award Recipients | Controlled Release Society (CRS)". www.controlledreleasesociety.org. Retrieved 2024-04-22.
- meet any of the eight academic-specific criteria
- or cite multiple reliable, secondary sources independent of the subject, which cover the subject in some depth
Make sure your draft meets one of the criteria above before resubmitting. Learn about mistakes to avoid when addressing this issue. If the subject does not meet any of the criteria, it is not suitable for Wikipedia.